Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.
IDT and Beijing-based ChosenMed plan to develop large pan-cancer panels as part of the Cancer Genome Atlas of China.
The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.
New instrument releases at this week's meeting reflected proteomics' increased emphasis on throughput and the continuing spread of ion mobility technology.
The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.
Danaher is offering 11 million shares of its common stock at $123 per share and 1.5 million shares of its mandatory convertible preferred stock at $1,000 per share.
Danaher has commenced its concurrent offerings of $1.35 billion of shares of its common stock and $1.35 billion of shares of its mandatory convertible preferred stock.
Danaher is financing the deal with $3 billion from an equity offering, cash on hand, and proceeds from an issuance of debt and/or new credit facilities.
The firm's Life Sciences segment grew 10 percent year over year during the quarter while its Diagnostics segment was up 4 percent.
Researchers showed that the test had equivalent results to a lab-based assay and has the potential for a faster turnaround time.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.